[We, the Italian physicians, and statins].
After marketing withdrawal of cerivastatin physicians asked several questions regarding the efficacy and safety of statins, the real risk of myopathy, the compared efficacy of all the statins, the reasons why severe adverse events could happen despite several long-term randomized controlled trials, the approval from regulatory agencies. This is the position statement of the Italian Federation of Cardiology. Synthetic answers to previous questions are addressed and few suggestions to avoid that similar conditions should occur again. Finally, the appropriate prescription of statins is recommended.
Bobbio
M
M
Divisione Universitaria di Cardiologia Azienda Ospedaliera San Giovanni Battista Corso Dogliotti, 14 10126 Torino. marcobobbio@libero.it
D004335:Drug and Narcotic Control; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007558:Italy; D017410:Practice Guidelines as Topic; D011364:Professional Practice; D011725:Pyridines / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D011725:Pyridines; C086276:cerivastatin
Noi, medici italiani, e le statine.